Roe M T, Ohman E M, Maas A C, Christenson R H, Mahaffey K W, Granger C B, Harrington R A, Califf R M, Krucoff M W
Duke Clinical Research Institute, Durham, North Carolina 27715, USA.
J Am Coll Cardiol. 2001 Jan;37(1):9-18. doi: 10.1016/s0735-1097(00)01101-3.
Successful reperfusion after acute myocardial infarction (MI) has traditionally been considered to be restoration of epicardial patency, but increasing evidence suggests that disordered microvascular function and inadequate myocardial tissue perfusion are often present despite infarct vessel patency. Thus, optimal reperfusion is being redefined to include intact microvascular flow and restored myocardial perfusion, as well as sustained epicardial patency. Coronary angiography has been used as the gold standard to define failed reperfusion, according to the Thrombolysis In Myocardial Infarction (TIMI) flow grades. However, new angiographic techniques, including the corrected TIMI frame count and myocardial blush grade, have been used to show that epicardial TIMI flow grade 3 may be an incomplete measure of reperfusion success. Furthermore, evolving noninvasive diagnostic techniques, including measurement of infarct size with cardiac marker release patterns or technetium-99m-sestamibi single-photon emission computed tomographic imaging and analysis of ST segment resolution appear to be useful complements to angiography for the assessment of myocardial tissue reperfusion. Promising adjunctive therapies that target microvascular dysfunction, including platelet glycoprotein IIb/IIIa inhibitors, and agents designed to improve tissue perfusion and attenuate reperfusion injury are being evaluated to further improve clinical outcomes after acute MI. To accelerate development of these new reperfusion regimens, an integrated approach to phase II clinical trials that incorporates multiple efficacy variables, including angiography and noninvasive biomarkers of microvascular dysfunction, should be considered. Thus, as the reperfusion era moves into the next millennium, the open-artery hypothesis is expected to shift downstream and guide efforts to further improve myocardial salvage and clinical outcomes after acute MI.
传统上,急性心肌梗死(MI)后的成功再灌注被认为是心外膜血管开通,但越来越多的证据表明,尽管梗死血管已开通,但微血管功能紊乱和心肌组织灌注不足的情况仍经常存在。因此,最佳再灌注正被重新定义,包括完整的微血管血流、恢复的心肌灌注以及持续的心外膜血管开通。根据心肌梗死溶栓(TIMI)血流分级,冠状动脉造影一直被用作定义再灌注失败的金标准。然而,包括校正TIMI帧数和心肌 blush 分级在内的新血管造影技术已被用于表明,心外膜 TIMI 血流 3 级可能是再灌注成功的不完整指标。此外,不断发展的非侵入性诊断技术,包括通过心脏标志物释放模式测量梗死面积或利用锝-99m- sestamibi 单光子发射计算机断层扫描成像以及 ST 段分辨率分析,似乎是血管造影评估心肌组织再灌注的有用补充。针对微血管功能障碍的有前景的辅助治疗方法,包括血小板糖蛋白 IIb/IIIa 抑制剂,以及旨在改善组织灌注和减轻再灌注损伤的药物正在进行评估,以进一步改善急性心肌梗死后的临床结局。为了加速这些新再灌注方案的开发,应考虑采用一种综合方法进行 II 期临床试验,该方法纳入多个疗效变量,包括血管造影和微血管功能障碍的非侵入性生物标志物。因此,随着再灌注时代进入下一个千年,开放动脉假说预计将向下游转移,并指导进一步改善急性心肌梗死后心肌挽救和临床结局的努力。